Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Endeavor Biomedicines, Inc.
Emory University
Milton S. Hershey Medical Center
Medical University of Vienna
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Augusta University
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
European Organisation for Research and Treatment of Cancer - EORTC
University of Zurich
Nationwide Children's Hospital
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fundación de investigación HM
Beijing Sanbo Brain Hospital
University of Virginia
Celgene
Memorial Sloan Kettering Cancer Center
Eastern Cooperative Oncology Group
University of Iowa
Children's Oncology Group
University of Colorado, Denver
Cairo University
University of Iowa
Wake Forest University Health Sciences
National Cancer Institute (NCI)
University of Iowa
Ann & Robert H Lurie Children's Hospital of Chicago
Washington University School of Medicine
Central Hospital, Nancy, France
National Cancer Institute (NCI)
University of Iowa
Novartis
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
National Cancer Institute (NCI)